SEC Filings

Exhibit 99.1

Poseida Therapeutics Appoints Charles M. Baum, M.D., Ph.D., to Board of Directors

SAN DIEGO, May 18, 2022 – Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced the appointment of Charles M. Baum, M.D., Ph.D., to its Board of Directors, effective May 16,... (continue reading...)

Exhibit 10.1

MariMed Inc.

SECOND AMENDMENT TO EMPLOYMENT AGREEMENT

Effective Date: May 12, 2022

This Second Amendment to the Employment Agreement (this “Agreement”) is between MARIMED INC., a Delaware corporation (the “Company” or “MariMed”), and JON R. LEVINE, an individual (the “Executive”).

WHEREAS, the Company and the Executive entered into an Employment Agreement effective as of dated July 1, 2021, as amended by the First Amendment to... (continue reading...)

Exhibit 99.1

IMMEDIATE NEWS RELEASE

SCHMITT INDUSTRIES ANNOUNCES IT HAS ENTERED INTO LOI FOR XACT ASSETS

PORTLAND, OR, May 17, 2022 – Schmitt Industries, Inc. (NASDAQ: SMIT) (the “Company” or “Schmitt”) announced that it has entered into a letter of intent to sell all assets related to its Xact business line. This potential transaction is subject to several contingencies, including the negotiation and execution of definitive transaction agreement,... (continue reading...)